Select Shred, Builder, or GLP-1
Branded Ozempic and Wegovy pens hide the math
The table below depicts the timing of when many GLP1 receptor agonists became commercially available
When compared to other strategies, GLP-1R agonists occupy an intermediate position, more effective than lifestyle or other pharmacological interventions, but less invasive than bariatric surgery, underscoring their unique therapeutic niche
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective therapies for patients with type 2 diabetes (T2D) and/or obesity, particularly for those with coexisting cardiovascular disease and/or high cardiovascular risk [1]
During ER stress, GRP78, the primary regulator of UPR, dissociates from the ER compartment, activating the main PERK protein pathway